tamoxifen

For me, I have restrained giving adjuvant chemotherapy to women over 60 with resected zero or few positive node breast cancer that was heavily ER positive. I thought Tamoxifen or AI was sufficient. Pretty much every other oncologist in town gave chemotherapy. Seemed excessive. (@davideyoungmd)

I had a lumpectomy in 2007 chemotherapy and radiotherapy followed by tamoxifen for ten years was called for a routine mammogram in 2021 and discovered another cancer in the same breast and had to have a mastectomy and chemotherapy That worry is still there (@Lizbookworm)

Hey Twitter buds please can you retweet til I hear from someone who can help with the following question Is taking one #Tamoxifen tablet every 2 days better than not taking it at all? Will it minimise side effects? @Liz_ORiordan hoping you can help? Thank you 😊 #breastcancer (@Mayle4thbewithu)

Can anyone who was at #ASCO2023 point me in the direction of the data that said it was better to take Tamoxifen at night? Saw it on a @Breastcancerorg summary (@Liz_ORiordan)

Good news for hot women! For those who do not want to take drugs research suggests that #acupuncture affects the hypoyhalamus pituitary-adrenal function. Also a study from Norway demonstrated that acu reduces #hotflashes in women medicated with #Tamoxifen after #breastcancer (@HervikJill)

This week, @prarthnavb & @drteplinsky presented at #TumorBoardTuesday on the use of low dose tamoxifen (TAM) to decrease #breastcancer recurrence. We're building the case wrap up which includes a special appearance by @drteplinsky set to drop tomorrow, Friday May 19! (@TumorBoardTues)

6/15 #TumorBoardTuesday #BreastCancer 👩🏻‍🏫Mini tweetorial 4 👩🏽‍🏫 📌Side effects of full dose tamoxifen: 🥵Hot flashes 🛏️Effect on sexual health 😐mood change 🩸VTE 🧠Stroke 🚺Endometrial cancer 👀Cataracts (@prarthnavb)

Could we be talking about slightly different things? I was wondering if about Tamoxifen for breast cancer risk reduction in unaffected women with Gail model 5 yr risk of >3% is the reduction in breast cancer for invasive ER pos disease or all subtypes #TumorBoardTuesday (@HannahAlison20)

13/15 #TumorBoardTuesday #BCSM #BreastCancer 💥Current guidelines for baby-TAM per @NCCN If patient ✔️symptomatic on 20mg dose ✔️“unwilling or unable to take standard dose” ✔️Can take 5mg tamoxifen for 3 years (@prarthnavb)

Only moments away…excited to 📚learn about new low dose tamoxifen strategies to prevent transformation/progression of high risk lesions in #breastcancer. Join @TumorBoardTues at 7 PM CST/8 PM EST to follow along! #TumorBoardTuesday (@JohnEbbenMDPhD)

I’m glad you brought this up. I’m ER+ 10% and my oncologist treated it like TNBC with chemo even though I was stage 1. But follow up care has been a nightmare. On tamoxifen but haven’t been clear how beneficial that is. And what else, if anything, I should be treated with (@FairUseLBR)

6/6 #TumorBoardTuesday Thursday Case🎀 🙏Look for changes w increased trials in variant histology 🤔Trials increasingly recognizing that UC= many diff phenotypes. ➡️Join us on 05/16 when @drteplinsky @prarthnavb present a case of utilizing low dose tamoxifen in #breastcancer! (@TumorBoardTues)

📳 Phase 3 DATA trial ❓Any role of extended AI in adjuvant breast cancer 🚫 No DFS or OS benefit by extending AI beyond 5 years after initial tamoxifen use @OncoAlert #MedTwitter @SuyogCancer @PTarantinoMD @breastcancer @hoperugo @jamecancerdoc https://t.co/LiXqtFepCS (@saadvikdr)

What's the likelihood of brain mets vs others? Seems like more people might be willing to take a drug if it has fewer side effects for only partially increased risk. Just perspective as someone on tamoxifen - don't know if other drugs are analogous. Life vs QoL balance. (@LoveNIntegrity)

I was stage 2 IDC with low Oncotype. Nothing in my lymph nodes. I was told chemo wouldn’t make any difference for me. Did my 5 years of tamoxifen/Anastrozole and here I am #mbc 8 years later. Mine was the “easy” breast cancer. ()

The reduced likelihood of receiving adjuvant endocrine therapy & ovarian suppression+ tamoxifen in premenopausal patients w/ HR+, HER2+ breast cancer may indicate an unclear role for these treatments in this pop. @JasmineSukumar @MDAndersonNews #bcsm https://t.co/HYqcJ1dSGg (@OncLive)

The reduced likelihood of receiving adjuvant endocrine therapy & ovarian suppression+ tamoxifen in premenopausal patients w/ HR+, HER2+ breast cancer may indicate an unclear role for these treatments in this pop. @JasmineSukumar @MDAndersonNews #bcsm https://t.co/khJ3H6Ivq0 (@OncLive)

To generate a mouse model of Wilms tumor, Vicki Huff's lab @MDAndersonNews knocked out Wt1 mosaically by titrating tamoxifen injections. But that is not enough to generate tumors. 2/3. (@rrbehringer)

Looking forward to @DrReshmaMahtani talk on Targeted therapy for ER+/HER2- MBC: CDK4/6 inhibition and beyond! Tamoxifen was one of the first precision Oncology drugs! @MiamiCancerInst #MCIPrecisionOncology @BaptistHealthSF (@BrainTumorDoc)

Very interesting analysis👏 by MD. Prudence Francis premenopause ER+ breast cancer: present, past, and future, OFS allows the use of adjuvant AI in premenopausal women as an alternative to tamoxifen, which can reduce the recurrence of ER+ HER2-neg. @SABCSSanAntonio #breastcancer (@Dr_Ivanoncologo)

Dr. Gokul Das shows disruption between ESR1-p53 with tamoxifen; Discussant Dr Deepali Sachdev highlights strategies to explore the clinical relevance of this interaction in follow-up studies. #SABCS22 (@DrSGraff)

💎#Desmoid 🔹Beta-catenin, CTNNB1 mutation Mx: 🔹Asymptomatic →Active surveillance, C-scope (FAP) 🔹Resection (30% recurrence) 🔹Unresectable/Recurrent/Margin+ →XRT 🔹Systemic Rx: Tamoxifen, NSAIDs, Chemotherapy and TKIs #MedTwitter #OncTwitter #sarcoma #oncology (@dawood_findakly)

.@RashmiChughMD et al. describe a novel PGR-NR4A3 gene fusion in a patient with extraskeletal myxoid chondrosarcoma having extraordinarily long-term clinical benefit to the use of tamoxifen. 👉 https://t.co/ohxHYoVQUF (@JCOPO_ASCO)

#ASCO22 #AMEERA6 👉Ongoing adjuvant P3 trial investigating #amcenestrant versus tamoxifen for patients with HR+HER2- early #breastcancer who discontinued adjuvant AI due to treatment-related toxicity @EORTC_BCG🤝@BIGagainstBC🤝@ALLIANCE_org @MeyskensT @EtienneB66 #bcsm @OncoAlert (@EORTC_BCG)

"Targeting ATR enhances the antitumor efficacy of HER3-DXd in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression" #AACR22 by our group. Excited with our late breaking presentaiton. https://t.co/GdHoDdRLUp #bcsm (@teamoncology)

What about Her2+ HR+? Adjuvant soc 10 years ago for small invasive tumors was no AI/ tamoxifen due to risk of uterine cancer. And mammo f/u doesn’t catch recurrence in a breast already removed. (@eccarville)

#SABCS2021 Tamoxifen and uterine cancer: Tam uterine cancers have fewer PIK3CA mutations. Tamoxifen can activate PI3K cross-talk which can be blocked by alpelisib in the uterus, so that tam-induced uterine CA does not need PIK3CA. Interesting biology. (@GeorgeSledge51)

We should reserve Cdk4/ 6i for 2 nd line and go for just tamoxifen or AI as first line tx for pts with advanced breast cancer @OncoAlert @myESMO @ASCO @oncology_bg @FDAOncology @ajumathew_ @TMC_BreastDMG @BreastCancerNow @SusannahStanwa1 @SusanGKomen @NancyGBrinker #ChooseWisely (@SirohiBhawna)

Details matter. Pt fails exp pi3k & MEK inh, trametinib & tamoxifen, & letrozole—but then has super response to trametinib & letrozole: “KRAS-mutated, ER-positive lserous ovarian cancer: Unraveling an exceptional response mystery” Kato KurzrockLab https://t.co/9uwgbGU8PY (@Dr_R_Kurzrock)

Great #SABCS20 presentation from Rinath Jeselsohn @DanaFarber on FOXA1 and #lobular #breastcancer - tamoxifen resistance, low grade luminal A with poor outcomes, potential targets. Still so much to learn! @Otto_DFCI @oesterreichs #bcsm #lobularbreastcancer (@LPseattle)

ICYMI: Abemaciclib/Tamoxifen Shows OS Benefit in HR+, HER2- Metastatic Breast Cancer and @ErikaHamilton9 is explaining more in this interview with @OncLive. https://t.co/eqSKdxwsYO (@SarahCannonDocs)

The addition of tamoxifen to abemaciclib resulted in an improvement in OS compared with abemaciclib monotherapy in patients with HR–positive, HER2-negative metastatic breast cancer. @myESMO @ErikaHamilton9 @SarahCannonDocs #ESMO20 #bcsm https://t.co/jdTuTf0kxo (@OncLive)

Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease https://t.co/vppHQwFDyM #bcsm #oncology #cancer #ESMO20 #ESMO2020 @ErikaHamilton9 (@ASCOPost)

Abemaciclib/Tamoxifen Shows OS Benefit in HR+, HER2- Metastatic Breast Cancer @ErikaHamilton9 @SarahCannonDocs @myESMO #ESMO20 #bcsm https://t.co/wsFK6t7fLp (@OncLive)

.@ErikaHamilton9 is featured in an oral presentation on Nextmonarch: Final Overall Survival Analysis Of Abemaciclib Monotherapy Or In Combination With Tamoxifen In Patients With HR+, HER2- Metastatic Breast Cancer. Don’t miss the #ESMO20 presentation, on demand all weekend. (@SarahCannonDocs)

Friends at #ESMO20 A pleasure to introduce our @OncoAlert 🚨 colleague @ErikaHamilton9 👩‍⚕️🇺🇸of @SarahCannonDocs presenting: #nextMONARCH 7.2 month improvement in OS with addition of tamoxifen to abemaciclib in advanced line HR+/HER2- #BreastCancer #BCSM Best, @weoncologists (@OncoAlert)

NextMonarch: abemaciclib +/- tamoxifen in advanced ER+/HER2- #breastcancer 🔸Addition of tamoxifen to abemaciclib improved OS(24 vs 17mo) but not PFS, ORR 🔸More Venous thromboembolism seen. 🔸Diarrhea can be improved with loperamide. #ESMO20 @OncoAlert #bcsm (@jesusanampa)

Dr.@ErikaHamilton9 presenting NextMONARCH at #ESMO20 #bcsm OS benefit from adding Tamoxifen to Abema in advanced line HR+/HER2- breast cancer. An option for patients who have not yet received a CdK inh? @OncoAlert #OncoAlert (@GaiaGriguolo)

Interesting concept to give adjuvant EGFR TKI long term. Maybe like tamoxifen in breast cancer. (@drgandara)